26 September 2022

Today sees the start of the 10th edition of the European Biotech Week , during which a series of events and happenings, online, onsite and hybrid, will take place across Europe to celebrate biotechnology and its applications in order to tell the story of a metasector that has innovation in its #DNA.

Apparently the historical period could not be better, even if the geopolitical situation is not bright, according to the index that aggregates the performance of listed companies in the sector, known as the Nasdaq Biotech Index, biotechnology companies have had a clear increase in the last five years in terms of both economic investment and human resources.

This is also confirmed in our country, which continues to distinguish itself both in terms of the number of events and the quality and quantity of attendance recorded, thanks to the involvement of numerous partners: from biotech companies to universities, from scientific research centres to schools and museums. In fact, the Italian biotech sector is experiencing constant growth, which, although slight, nevertheless reveals a strong intensity in R&D investments, with peaks of excellence both in the bioeconomy and in the area of human health.

If one had to make a ranking, at the moment in Italy the driving force in the sector would be health biotechnology, followed by industrial biotechnology and environmental biotechnology companies. Last, but not least, would be Gpta, i.e., those companies that include genomic biotechnology, proteomic biotechnology and advanced technologies.

The motivation? Biotechnology companies active in the field of human health continue to account for the majority share of the Italian market because they play a crucial role in the achievement of new social goals, dealing with the search for increasingly targeted and effective answers in relation to the growing demand for health of the population. It is precisely this need that sustains a sector populated by stable companies, which manages to produce up to about three quarters of the sector’s total turnover.

Taking a territorial analysis, in recent years there has been a gradual spread of the biotech production structure throughout the country: almost all the northern regions have been confirmed as major centres of biotech production and turnover, with the Lombardy region acting as the leader, but the Mezzogiorno has also recorded growth, especially in the industrial biotechnology sector.
In addition to total turnover, Italy’s position certainly stands out in terms of dynamism, size and investments made in research and development by sector companies and production chains: it is clear that Italian companies are among the leading players on the European and global scene.

It is not just a matter of business, technologies play a crucial role in achieving new social, environmental and industrial goals, and it is for these reasons that it is important to tell even the uninitiated about the value of biotechnology, disclosing to a wide audience the countless applications and the extraordinary potential in meeting the challenges of health, sustainable development and economic recovery.

Values also shared by the Sapio Group, whose ‘purpose’ is the advancement not only of itself, but also of the community, is to become a forge for the development of new technologies and new ideas to improve people’s quality of life and the environment in which we live. The expertise, specialisation and profound know-how of gases and their applications acquired by the Sapio Group are placed at the service of the most advanced scientific research, biology, the medical world and pharmaceutical companies.
Don’t miss the various appointments of this edition! Click on the calendar